Biotech Specialty Pharma

Opexa Therapeutics

2635 Technology Forest Blvd.
The Woodlands, TX 77381 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Develops treatments for autoimmune diseases.

Management Neil Warma, President and Chief Executive Officer; Jaye Thompson, Ph.D.,Senior-Vice President of Clinical Development and Regulatory Affairs; Don Healy Ph.D., Vice-President of Scientific Development and Manufacturing; Donna R. Rill, Senior Vice-President of Operations; John Ginzler, Vice-President of Finance;

Click here for Financial Data
Keywords: Regenerative medicine, immunotherapy, multiple sclerosis, secondary progressive multiple sclerosis, inflammatory disease, MS

Comment


Updated: Mar. 31, 2015


Description

Opexa Therapeutics (Nasdaq: OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS......view more

Products / Services

Opexa has recently rebranded its lead therapy with the new name, Tcelna. The product was previously known as Tovaxin. The rebranding of Tcelna encompasses the advancements made to the manufacturing p......view more

Technology / Differentiation

Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPath, Opexa's proprietary method for the production of a patient-spec...view more

Market / Customers

The company's product candidates have the potential to offer enhanced efficacy, safety and tolerability to address the significant unmet medical needs in several large patient populations. Tcelna h......view more


Status

Opexa's lead product, Tcelna (formerly Tovaxin), is a novel T-cell immunotherapy positioned to enter Phase IIb clinical development for the treatment of patients with Secondary Progressive MS (SP-MS...view more

RELATED COMPANIES



0000-00-00-15117